 KalVista Pharmaceuticals, Inc. NASDAQ: KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors today provided an operational update and released financial results for the fiscal year ended April 30, 2020. 